因诺惟康 | InnoVecBio

— biomedical new technologies

生物医学新技术

针对RDH12变异引起的视网膜变性的基因治疗技术

了解更多

公司新闻

— Company news

InnoVec Completes Series A+ Financing to Advance Gene Delivery Technologies and Accelerate Clinical Trials of Therapeutic Candidates.

Beijing Innovec Medical Technology Co., Ltd. (hereinafter referred to as "Innovec") has completed a Series A+ financing round worth tens of millions of yuan. This round was led by Tianchuang Capita...

InnoVec-Kunhua Hospital Collaborative Study (IF=12.5) Uncovers Link Between Interferon-Induced Guanylate-Binding Proteins and Sarcopenia

Published Findings:Landmark Discovery: First evidence connecting specificinterferon-induced guanylate-binding proteins (GBPs) to sarcopenia pathogenesisHigh-Impact Publication: Featured in top-tier...

InnoVec Completes Series A+ Financing to Advance Gene Delivery Technologies and Accelerate Clinical Trials of Therapeutic Candidates.

InnoVec-Kunhua Hospital Collaborative Study (IF=12.5) Uncovers Link Between Interferon-Induced Guanylate-Binding Proteins and Sarcopenia

InnoVec and Yunnan Kunhua Hospital Publish Groundbreaking Study (IF=6.6) on Tumor Heterogeneity in Hepatosplenic T-cell Lymphoma

InnoVec Biotherapeutics Awarded Third Prize in Innovation Category at 4th "Entrepreneur Beijing" Competition

Team Building Adventure: Universal Studios Beijing – Let's Go!

InnoVec's IVB102 Granted FDA Rare Pediatric Disease Designation for XLRS Gene Therapy

service qrcode

扫码关注

京ICP备2021023611号

©2026 INNOVEC

京ICP备2021023611号-1